FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel
Status:
Recruiting
Trial end date:
2022-03-15
Target enrollment:
Participant gender:
Summary
The primary objective of the phase II trial is to determine the efficacy and safety of a
combination of Durvalumab with the Carboplatin/Paclitaxel as first line treatment in patients
with recurrent/metastatic SCCHN not eligible to standard chemotherapy.